Is the A2 Milk (ASX:A2M) share price dirt cheap?

Is it time to buy A2 Milk shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The A2 Milk Company Ltd (ASX: A2M) share price was out of form again on Monday.

The embattled infant formula company's shares dropped 2.5% to $6.23.

This means A2 Milk's shares are now down almost 16% over the last three weeks.

Group of thoughtful business people with eyeglasses reading documents in the office.

Image source: Getty Images

Is the A2 Milk share price good value now?

Positively for its long-suffering shareholders, one leading broker continues to see value in the A2 Milk share price at the current level.

According to a note out of Bell Potter this morning, its analysts have retained their buy rating and $7.70 price target on its shares.

Based on the current A2 Milk share price, this implies potential upside of ~24% for investors.

What did the broker say?

Bell Potter has been looking at recent industry data to get a picture of how A2 Milk is performing.

While the broker acknowledges that China's infant formula import volumes continue to demonstrate double digit year on year declines, it highlights that volumes are improving. For example, September volumes were down 24% year on year but up 10% month on month.

Outside this, Bell Potter continues to believe that the A2 Milk share price is not reflective of its turnaround potential. Particularly given its belief that the company could double its earnings by FY 2026.

It explained: "There is no change to our Buy rating. We see the scope for EPS to double by FY26e, if A2M can execute on the China offline expansion strategy, while recovering 50% of the lost sales (from FY20-21) in English label IMF. Exiting the loss making US assets or navigating a turnaround at the MVM asset would likely accelerate this turnaround. We do not see the current share price as reflecting this potential."

All in all, the broker appears to see this as a buying opportunity for investors.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: What this leading broker is saying about Lynas shares

Is it bullish or bearish? Let's find out.

Read more »

share buyers, investors, happy investors
Broker Notes

Bell Potter's top ASX 200 holdings revealed

These are the top holdings in the broker's core portfolio.

Read more »

An athlete runs fast with a trail of yellow smoke billowing out behind him.
Broker Notes

Up 139% in a year, why this buy rated ASX All Ords rare earths stock could keep racing higher

A leading broker forecasts more outperformance to come from this surging ASX rare earths stock.

Read more »

Miner with thumbs up at a mine.
Gold

2 ASX gold miners to buy for solid share price gains, according to Barrenjoey

The Africa-focused companies are deeply undervalued after recent sell-offs, the broker says.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »